Full-length MSP1 is a major target of protective immunity after controlled human malaria infection
Open Access
- 20 May 2024
- journal article
- research article
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 7 (8) , e202301910
Abstract
The merozoite surface protein 1 (MSP1) is the most abundant protein on the surface of the invasive merozoite stages ofPlasmodium falciparumand has long been considered a key target of protective immunity. We used samples from a single controlled human malaria challenge study to test whether the full-length version of MSP1 (MSP1FL) induced antibodies that mediated Fc-IgG functional activity in five independent assays. We found that anti-MSP1FLantibodies induced complement fixation via C1q, monocyte-mediated phagocytosis, neutrophil respiratory burst, and natural killer cell degranulation as well as IFNγ production. Activity in each of these assays was strongly associated with protection. The breadth of MSP1-specific Fc-mediated effector functions was more strongly associated with protection than the individual measures and closely mirrored what we have previously reported using the same assays against merozoites. Our findings suggest that MSP1FLis an important target of functional antibodies that contribute to a protective immune response against malaria.Keywords
Funding Information
- Alexander von Humboldt Foundation (3.2 − 1184811 -KEN - SKP)
- Wellcome Trust (107499)
- EC |H2020 | ERA-LEARN | European and Developing Countries Clinical Trials Partnership (TMA 2015 SF1001)
- NIHR Global Health Research Unit (16/136/33)
- DELTAS Africa Initiative (107754/Z/15/Z, DEL-15-003)
- Wellcome Trust (226669/Z/22/Z)
This publication has 77 references indexed in Scilit:
- Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trialThe Lancet, 2024
- Polyclonal epitope mapping reveals temporal dynamics and diversity of human antibody responses to H5N1 vaccinationCell Reports, 2021
- Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trialThe Lancet, 2015
- Human Antibodies Fix Complement to Inhibit Plasmodium falciparum Invasion of Erythrocytes and Are Associated with Protection against MalariaImmunity, 2015
- A threshold concentration of anti-merozoite antibodies is required for protection from clinical episodes of malariaVaccine, 2013
- ChAd63-MVA–vectored Blood-stage Malaria Vaccines Targeting MSP1 and AMA1: Assessment of Efficacy Against Mosquito Bite Challenge in HumansMolecular Therapy, 2012
- Merozoite surface proteins of the malaria parasite: The MSP1 complex and the MSP7 familyInternational Journal for Parasitology, 2010
- Secondary processing of the Plasmodium falciparum merozoite surface protein-1 (MSP1) by a calcium-dependent membrane-bound serine protease: shedding of MSP133 as a noncovalently associated complex with other fragments of the MSP1Molecular and Biochemical Parasitology, 1992
- Allelic dimorphism in a surface antigen gene of the malaria parasite Plasmodium falciparumJournal of Molecular Biology, 1987
- Gamma-Globulin and Acquired Immunity to Human MalariaNature, 1961